☰

Seth Zost - Publications

Affiliations: 
2018- Pediatrics Vanderbilt University School of Medicine, Nashville, TN, United States 
Tree Info Similar researchers PubMed Report error

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Desautels TA, Arrildt KT, Zemla AT, Lau EY, Zhu F, Ricci D, Cronin S, Zost SJ, Binshtein E, Scheaffer SM, Dadonaite B, Petersen BK, Engdahl TB, Chen E, Handal LS, et al. Computationally restoring the potency of a clinical antibody against Omicron. Nature. PMID 38720086 DOI: 10.1038/s41586-024-07385-1  0.803
2023 Wall SC, Suryadevara N, Kim C, Shiakolas AR, Holt CM, Irbe EB, Wasdin PT, Suresh YP, Binshtein E, Chen EC, Zost SJ, Canfield E, Crowe JE, Thompson-Arildsen MA, Sheward DJ, et al. SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes. Cell Reports. Medicine. 101267. PMID 37935199 DOI: 10.1016/j.xcrm.2023.101267  0.77
2023 Hou YJ, Chiba S, Leist SR, Meganck RM, Martinez DR, Schäfer A, Catanzaro NJ, Sontake V, West A, Edwards CE, Yount B, Lee RE, Gallant SC, Zost SJ, Powers J, et al. Host range, transmissibility and antigenicity of a pangolin coronavirus. Nature Microbiology. 8: 1820-1833. PMID 37749254 DOI: 10.1038/s41564-023-01476-x  0.468
2023 Chen EC, Gilchuk P, Zost SJ, Ilinykh PA, Binshtein E, Huang K, Myers L, Bonissone S, Day S, Kona CR, Trivette A, Reidy JX, Sutton RE, Gainza C, Diaz S, et al. Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes. Cell Reports. 42: 112370. PMID 37029928 DOI: 10.1016/j.celrep.2023.112370  0.814
2022 Desautels TA, Arrildt KT, Zemla AT, Lau EY, Zhu F, Ricci D, Cronin S, Zost SJ, Binshtein E, Scheaffer SM, Engdahl TB, Chen E, Goforth JW, Vashchenko D, Nguyen S, et al. Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants. Biorxiv : the Preprint Server For Biology. PMID 36324800 DOI: 10.1101/2022.10.21.513237  0.806
2022 Zost SJ, Vogt MR. A counterintuitive antibody cocktail disrupts coxsackievirus. Cell Host & Microbe. 30: 1194-1195. PMID 36108609 DOI: 10.1016/j.chom.2022.08.010  0.788
2022 Suryadevara N, Gilchuk P, Zost SJ, Mittal N, Zhao LL, Crowe JE, Carnahan RH. Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape. Star Protocols. 3: 101387. PMID 35578733 DOI: 10.1016/j.xpro.2022.101387  0.541
2022 VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE, Purcell LA, Kawaoka Y, Corti D, Fremont DH, Diamond MS. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nature Medicine. PMID 35046573 DOI: 10.1038/s41591-021-01678-y  0.583
2021 VanBlargan L, Errico J, Halfmann P, Zost S, Crowe J, Purcell L, Kawaoka Y, Corti D, Fremont D, Diamond M. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Research Square. PMID 34981042 DOI: 10.21203/rs.3.rs-1175516/v1  0.583
2021 Gilchuk P, Thomsen I, Yoder S, Brady E, Chappell JD, Stevens LJ, Denison MR, Sutton RE, Chen RE, VanBlargan LA, Suryadevara N, Zost SJ, Schmitz J, Pulley JM, Diamond MS, et al. Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. Iscience. 103602. PMID 34901783 DOI: 10.1016/j.isci.2021.103602  0.622
2021 Gilchuk P, Murin CD, Cross RW, Ilinykh PA, Huang K, Kuzmina N, Borisevich V, Agans KN, Geisbert JB, Zost SJ, Nargi RS, Sutton RE, Suryadevara N, Bombardi RG, Carnahan RH, et al. Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell. 184: 5593-5607.e18. PMID 34715022 DOI: 10.1016/j.cell.2021.09.035  0.62
2021 Kramer KJ, Johnson NV, Shiakolas AR, Suryadevara N, Periasamy S, Raju N, Williams JK, Wrapp D, Zost SJ, Walker LM, Wall SC, Holt CM, Hsieh CL, Sutton RE, Paulo A, et al. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Reports. 109784. PMID 34592170 DOI: 10.1016/j.celrep.2021.109784  0.659
2021 Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, Chen RE, Case JB, Sutton RE, Gilchuk P, Rodriguez J, Armstrong E, Gainza C, Nargi RS, Binshtein E, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nature Microbiology. PMID 34548634 DOI: 10.1038/s41564-021-00972-2  0.834
2021 Chen EC, Gilchuk P, Zost SJ, Suryadevara N, Winkler ES, Cabel CR, Binshtein E, Chen RE, Sutton RE, Rodriguez J, Day S, Myers L, Trivette A, Williams JK, Davidson E, et al. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. Cell Reports. 109604. PMID 34411541 DOI: 10.1016/j.celrep.2021.109604  0.744
2021 Zost SJ, Dong J, Gilchuk IM, Gilchuk P, Thornburg NJ, Bangaru S, Kose N, Finn JA, Bombardi R, Soto C, Chen EC, Nargi RS, Sutton RE, Irving RP, Suryadevara N, et al. Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. The Journal of Clinical Investigation. PMID 34156974 DOI: 10.1172/JCI146791  0.684
2021 Chen RE, Winkler ES, Case JB, Aziati ID, Bricker TL, Joshi A, Darling TL, Ying B, Errico JM, Shrihari S, VanBlargan LA, Xie X, Gilchuk P, Zost SJ, Droit L, et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. PMID 34153975 DOI: 10.1038/s41586-021-03720-y  0.514
2021 Guthmiller JJ, Utset HA, Henry C, Li L, Zheng NY, Sun W, Costa Vieira M, Zost S, Huang M, Hensley SE, Cobey S, Palese P, Wilson PC. An Egg-Derived Sulfated -Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. Mbio. e0083821. PMID 34126773 DOI: 10.1128/mBio.00838-21  0.56
2021 Diamond M, Chen R, Winkler E, Case J, Aziati I, Bricker T, Joshi A, Darling T, Ying B, Errico J, Shrihari S, VanBlargan L, Xie X, Gilchuk P, Zost S, et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Research Square. PMID 34013259 DOI: 10.21203/rs.3.rs-448370/v1  0.532
2021 Chen EC, Gilchuk P, Zost SJ, Suryadevara N, Winkler ES, Cabel CR, Binshtein E, Sutton RE, Rodriguez J, Day S, Myers L, Trivette A, Williams JK, Davidson E, Li S, et al. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. Biorxiv : the Preprint Server For Biology. PMID 33972937 DOI: 10.1101/2021.05.02.442326  0.746
2021 Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, Nargi RS, Sutton RE, Winkler ES, Chen EC, Fouch ME, Davidson E, Doranz BJ, Chen RE, Shi PY, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. PMID 33773105 DOI: 10.1016/j.cell.2021.03.029  0.792
2021 Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, Zost SJ, Jang H, Huang Y, Allen JD, Case JB, Sutton RE, Carnahan RH, Darling TL, Boon ACM, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. PMID 33691139 DOI: 10.1016/j.cell.2021.02.026  0.561
2021 Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, Liu J, Errico JM, Xie X, Suryadevara N, Gilchuk P, Zost SJ, Tahan S, Droit L, Turner JS, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature Medicine. PMID 33664494 DOI: 10.1038/s41591-021-01294-w  0.628
2021 Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, Chen RE, Case JB, Sutton RE, Gilchuk P, Rodriguez J, Armstrong E, Gainza C, Nargi RS, Binshtein E, et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. Biorxiv : the Preprint Server For Biology. PMID 33532768 DOI: 10.1101/2021.01.27.428529  0.826
2021 Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, Nargi RS, Sutton RE, Winkler ES, Chen EC, Fouch ME, Davidson E, Doranz BJ, Carnahan RH, Thackray LB, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Biorxiv : the Preprint Server For Biology. PMID 33501445 DOI: 10.1101/2021.01.19.427324  0.792
2020 Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Zost SJ, Jang H, Huang Y, Allen JD, Case JB, Sutton RE, Carnahan RH, Darling TL, Boon ACM, Mack M, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection. Biorxiv : the Preprint Server For Biology. PMID 33398272 DOI: 10.1101/2020.12.28.424554  0.572
2020 Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, Dingens AS, Nargi RS, Sutton RE, Suryadevara N, Rothlauf PW, et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host & Microbe. PMID 33259788 DOI: 10.1016/j.chom.2020.11.007  0.594
2020 Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, Dingens AS, Nargi RS, Sutton RE, Suryadevara N, Rothlauf PW, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Biorxiv : the Preprint Server For Biology. PMID 32935107 DOI: 10.1101/2020.09.10.292078  0.595
2020 Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Martinez DR, Williamson LE, Chen EC, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. PMID 32668443 DOI: 10.1038/S41586-020-2548-6  0.824
2020 Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Chen EC, Binshtein E, Shrihari S, Ostrowski M, Chu HY, Didier JE, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nature Medicine. PMID 32651581 DOI: 10.1038/S41591-020-0998-X  0.825
2020 Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Chen EC, Binshtein E, Shrihari S, Ostrowski M, Chu HY, Didier JE, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Biorxiv : the Preprint Server For Biology. PMID 32511414 DOI: 10.1101/2020.05.12.091462  0.825
2020 Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Williamson LE, Chen EC, Jones T, Day S, Myers L, et al. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. Biorxiv : the Preprint Server For Biology. PMID 32511409 DOI: 10.1101/2020.05.22.111005  0.829
2019 Zost SJ, Lee J, Gumina ME, Parkhouse K, Henry C, Wu NC, Lee CD, Wilson IA, Wilson PC, Bloom JD, Hensley SE. Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans. Cell Reports. 29: 4460-4470.e8. PMID 31875553 DOI: 10.1016/J.Celrep.2019.11.084  0.607
2019 Gouma S, Zost SJ, Parkhouse K, Branche A, Topham DJ, Cobey S, Hensley SE. Comparison of human H3N2 antibody responses elicited by egg-based, cell-based, and recombinant protein-based influenza vaccines during the 2017-2018 season. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31598646 DOI: 10.1093/Cid/Ciz996  0.339
2019 Lee JM, Eguia R, Zost SJ, Choudhary S, Wilson PC, Bedford T, Stevens-Ayers T, Boeckh M, Hurt AC, Lakdawala SS, Hensley SE, Bloom JD. Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin. Elife. 8. PMID 31452511 DOI: 10.7554/Elife.49324  0.347
2019 Altman MO, Angel M, Košík I, Trovão NS, Zost SJ, Gibbs JS, Casalino L, Amaro RE, Hensley SE, Nelson MI, Yewdell JW. Human Influenza A Virus Hemagglutinin Glycan Evolution Follows a Temporal Pattern to a Glycan Limit. Mbio. 10. PMID 30940704 DOI: 10.1128/Mbio.00204-19  0.511
2018 Zost SJ, Wu NC, Hensley SE, Wilson IA. Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens. The Journal of Infectious Diseases. PMID 30535315 DOI: 10.1093/Infdis/Jiy696  0.56
2018 Pardi N, Parkhouse K, Kirkpatrick E, McMahon M, Zost SJ, Mui BL, Tam YK, Karikó K, Barbosa CJ, Madden TD, Hope MJ, Krammer F, Hensley SE, Weissman D. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nature Communications. 9: 3361. PMID 30135514 DOI: 10.1038/S41467-018-05482-0  0.412
2017 Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proceedings of the National Academy of Sciences of the United States of America. PMID 29109276 DOI: 10.1073/Pnas.1712377114  0.449
2017 Wu NC, Zost SJ, Thompson AJ, Oyen D, Nycholat CM, McBride R, Paulson JC, Hensley SE, Wilson IA. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. Plos Pathogens. 13: e1006682. PMID 29059230 DOI: 10.1371/Journal.Ppat.1006682  0.42
2014 Linderman SL, Chambers BS, Zost SJ, Parkhouse K, Li Y, Herrmann C, Ellebedy AH, Carter DM, Andrews SF, Zheng NY, Huang M, Huang Y, Strauss D, Shaz BH, Hodinka RL, et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proceedings of the National Academy of Sciences of the United States of America. 111: 15798-803. PMID 25331901 DOI: 10.1073/Pnas.1409171111  0.392
Show low-probability matches.